Lakefront Biotherapeutics Nv

This study tested an oral medication called GLPG3667 in 186 adults with active systemic lupus erythematosus (SLE). Participants took the drug or a placebo once daily for 48 weeks. The goal was to see if the drug could reduce lupus disease activity and improve symptoms, while moni…

This study tested an oral drug called GLPG3667 (Cadefrecitinib) in 40 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Participants took the drug or a placebo daily for 24 weeks to see if it improves symptoms. The trial is complete, and results w…